Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 16/20 | 0.62 |
| ▸ | MAPK9 | P45984 | 9/20 | 0.62 |
| ▸ | CDK2 | P24941 | 8/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | CDK1 | P06493 | 1/20 | 0.57 |
| ▸ | CDK4 | P11802 | 1/20 | 0.57 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.57 |
| ▸ | CCND1 | P24385 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473570 | 1.00 | MAPK8 (0.62) | MAPK8MAPK9CDK2MAPK10CCNE1 | |
| SCHEMBL473564 | 0.90 | MAPK8 (0.68) | MAPK8MAPK9CDK2MAPK10CCNE1 | |
| SCHEMBL5097018 | 0.84 | MAPK10 (0.64) | MAPK8MAPK9CDK2MAPK10CCNE1 | |
| SCHEMBL473555 | 0.82 | MAPK10 (0.69) | MAPK8MAPK9CDK2MAPK10CCNE1 | |
| SCHEMBL473447 | 0.78 | MAPK8 (0.78) | MAPK8MAPK9CDK2MAPK10CCNE1 | |
| SCHEMBL473422 | 0.78 | MAPK8 (0.75) | MAPK8MAPK9CDK2MAPK10CCNE1 | |
| SCHEMBL473449 | 0.78 | MAPK8 (0.78) | MAPK8MAPK9CDK2MAPK10CCNE1 | |
| SCHEMBL473500 | 0.78 | MAPK8 (0.79) | MAPK8MAPK9CDK2MAPK10CCNE1 | |
| SCHEMBL473501 | 0.78 | MAPK8 (0.79) | MAPK8MAPK9CDK2MAPK10CCNE1 | |
| SCHEMBL4133952 | 0.78 | MAPK8 (0.72) | MAPK8MAPK9CDK2MAPK10CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962622-B2 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2066319-B1 | BENZOTRIAZOLE KINASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-20080103142-A1 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103142-A1 | Benzotriazole kinase modulators | CDK1, CDK3, MAPK1 | MAPK8 61/4885MAPK9 65/4885CDK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.